hotspot -WSS

hotspot

author：focus 2025-09-28 18:30:47 - browse：45

Three boxes of Wegovy stands in a line — coverage from STAT — Steffen Trumpf/picture alliance/Getty Images

WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to the drug for people on Medicare, experts told STAT.

Currently, Medicare is prohibited by law from covering medications for obesity treatment alone. While companies that manufacture wildly popular anti-obesity medications and their allies haven’t been successful in lobbying Congress to change the law, the Food and Drug Administration’s move could give doctors an avenue to prescribe the medications to some Medicare patients.

Wegovy’s new label indicates that the drug can be used to reduce the risk of major heart complications for people who are overweight or obese and have existing heart disease, Novo said in a statement Friday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Removing probiotics from the NICU could threaten preemies' health

WSS

10 million people disenrolled from Medicaid over past six months

STAT Executive Editor Rick Berke on STAT's 8th birthday

A clever new way to fix Medicaid and graduate medical education

Microbiome research is starting to find links to chronic diseases

Victims of gun violence feel impacts long after bullet wound

Emergency workers more likely to restrain Black patients: study

Wikipedia

hotspot

leisure time

Heart attack and stroke risk calculators need revising

Victims of gun violence feel impacts long after bullet wound

Novavax promises a turnaround & Lilly roils the obesity market

Drug for rare kidney disease narrowly misses mark in clinical trial

Supreme Court strikes down use of affirmative action

Extreme heat events are a public health emergency

Tori Bowie and the unacceptable rates of Black maternal death

Removing probiotics from the NICU could threaten preemies' health

Novavax promises a turnaround & Lilly roils the obesity market

The Sacklers, horror, and ‘The Fall of the House of Usher’

knowledge

Drug for rare kidney disease narrowly misses mark in clinical trial

Experts study whether long Covid risk adds up with each reinfection

EpiPen alternative approval delay highlights citizen petition issue

Lasker Awards 2023: Winners in biomedical research

Thermo Fisher plant for manufacturing gene therapies to expand

Study: New antibiotic targets gonorrhea as well as last existing drug

entertainment

hotspot

focus

entertainment